Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Connect Biopharma HoldingsCNTB +1.15%7 Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus rates CNTB with a GF Score™ of 7/100. The stock has 3 warning signs investors should review. Among 971 Biotechnology companies, Connect Biopharma Holdings ranks better than 87.74% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Connect Biopharma Holdings's Debt-to-Equity or its related term are showing as below:
CNTB'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.02
Current: 0.02
During the past 7 years, the highest Debt-to-Equity Ratio of Connect Biopharma Holdings was 0.02. The lowest was 0.00. And the median was 0.00.
CNTB's Debt-to-Equity is ranked better than 87.74% of 971
companies
in the Biotechnology industry
Industry Median: 0.16
vs CNTB: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Connect Biopharma Holdings Debt-to-Equity Related Terms
Connect Biopharma Holdings Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNTB vs CUE, HURA, CDXS: Debt-to-Equity Comparison
For the Biotechnology subindustry, Connect Biopharma Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Connect Biopharma Holdings Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Connect Biopharma Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Connect Biopharma Holdings (CNTB) has a Debt-to-Equity of 0.02 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Connect Biopharma Holdings and its competitors. According to the industry distribution chart, Connect Biopharma Holdings ranks #119 out of 971 companies in the Biotechnology industry, placing it in the top 12.3%.
Is Connect Biopharma Holdings' Debt-to-Equity too high?
Connect Biopharma Holdings' current Debt-to-Equity is 0.02. The Biotechnology industry median Debt-to-Equity is 0.16. Connect Biopharma Holdings' value of 0.02 is 87.5% below this industry median. Based on the distribution chart, Connect Biopharma Holdings ranks #119 out of 971 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Connect Biopharma Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Connect Biopharma Holdings' Debt-to-Equity compare to CUE and HURA?
According to the Biotechnology industry distribution chart, Connect Biopharma Holdings ranks #119 out of 971 companies for Debt-to-Equity. This places Connect Biopharma Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Connect Biopharma Holdings' value of 0.02 is 87.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 971 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Connect Biopharma Holdings's current Debt-to-Equity of 0.02 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Connect Biopharma Holdings and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Connect Biopharma Holdings's current Debt-to-Equity is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Connect Biopharma Holdings stock overvalued right now?
Connect Biopharma Holdings (CNTB) has a current Debt-to-Equity of 0.02. The current Debt-to-Equity is 0.02 and 87.5% below the Biotechnology industry median of 0.16. Connect Biopharma Holdings' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Connect Biopharma Holdings (CNTB), the current Debt-to-Equity is 0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
7GF Score
Get the complete analysis for CNTB
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTB has been successfully added to your 
